glp 1 for cosmetic weight loss GLP-1 Injections: 10 FAQs, Answered Modern Wellness Weight Loss Program

The drug could see FDA approval in 2027, according to GoodRx

This 72-week study compared the efficacy and safety of subcutaneous semaglutide 7.2 mg against semaglutide 2.4 mg and a placebo, all administered weekly, in 1,407 adults with obesity who also participated in lifestyle interventions

The authors conducted a two-year observational study that explored changes in body weight, cardiometabolic and endocrine parameters in obese women with PCOS who continued taking metformin after stopping semaglutide

Of all demographic groups, women between the ages of 50 and 64 had the highest use rate: One in five women, or 20 percent, reported having ever used GLP-1 agonists